Format

Send to

Choose Destination
Ther Adv Endocrinol Metab. 2012 Apr;3(2):55-9. doi: 10.1177/2042018812437181.

Efficacy and safety of ultra-long-acting insulin degludec.

Abstract

All patients with type 1 diabetes and significant numbers of those with type 2 diabetes are treated with insulin. Nonadherence to insulin regimen can impact glycaemic control. Insulin degludec is a new generation, ultra-long-acting basal insulin that forms soluble multihexamers at the injection site that slowly release insulin degludec monomers into the circulation giving a prolonged duration of action. Insulin degludec may provide a safe and convenient dosing option for patients who require some flexibility in adhering to an insulin regimen according to their lifestyle or circumstances. In this review we focus on the early phases of insulin degludec development.

KEYWORDS:

hypoglycaemia; insulin degludec; type 1 and type 2 diabetes; ultra-long-acting basal insulin

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center